Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

c-MYC anticorps

MYC Reactivité: Humain, Souris, Rat WB, IF, FACS, IHC (p) Hôte: Souris Monoclonal 9E10-3 unconjugated
N° du produit ABIN3025109
  • Antigène Voir toutes c-MYC (MYC) Anticorps
    c-MYC (MYC) (Myc Proto-Oncogene protein (MYC))
    Reactivité
    • 351
    • 166
    • 119
    • 15
    • 14
    • 13
    • 13
    • 13
    • 9
    • 9
    • 8
    • 6
    • 6
    • 6
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain, Souris, Rat
    Hôte
    • 279
    • 92
    • 6
    • 3
    • 2
    • 1
    Souris
    Clonalité
    • 272
    • 110
    Monoclonal
    Conjugué
    • 186
    • 31
    • 24
    • 24
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 8
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp c-MYC est non-conjugé
    Application
    • 284
    • 141
    • 91
    • 78
    • 74
    • 58
    • 53
    • 28
    • 26
    • 15
    • 14
    • 13
    • 12
    • 11
    • 7
    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Attributs du produit
    It recognizes a transcription factor of 64-67 kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease.
    Purification
    Protein G affinity chromatography
    Immunogène
    Amino acids AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA were used as the immunogen for the c-Myc antibody.
    Clone
    9E10-3
    Isotype
    IgG1 kappa
    Top Product
    Discover our top product MYC Anticorps primaire
  • Indications d'application
    Optimal dilution of the c-Myc antibody should be determined by the researcher.

    1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Tris with 1  mM EDTA,  pH 9.0, for 10-20 min followed by cooling at RT for 20 min
    2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL,Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2)

    Restrictions
    For Research Use only
  • Concentration
    0.2 mg/mL
    Buffer
    0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store the c-Myc antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
  • Antigène
    c-MYC (MYC) (Myc Proto-Oncogene protein (MYC))
    Autre désignation
    C-Myc (MYC Produits)
    Synonymes
    anticorps MRTL, anticorps MYCC, anticorps bHLHe39, anticorps c-Myc, anticorps CMYC, anticorps c-myc, anticorps C-MYC, anticorps LOC100136746, anticorps ARC, anticorps B430311C09Rik, anticorps MYC, anticorps NOP, anticorps Nop30, anticorps RNCMYC, anticorps mMyc, anticorps AU016757, anticorps Myc2, anticorps Niard, anticorps Nird, anticorps cmyc, anticorps zc-myc, anticorps c-myc II, anticorps myc-B, anticorps myc2, anticorps myc1, anticorps CMyc, anticorps zgc:55680, anticorps CG10798, anticorps D-Myc, anticorps DM, anticorps DMYc, anticorps Dm, anticorps Dmel\CG10798, anticorps Dmyc, anticorps EG:BACN5I9.1, anticorps anon-WO03040301.171, anticorps bHLHe57, anticorps c-MYC, anticorps d-myc, anticorps dMYC, anticorps dMyc, anticorps dMyc1, anticorps da, anticorps dm, anticorps dm/dMyc, anticorps dm/myc, anticorps dmyc, anticorps dmyc1, anticorps l(1)G0139, anticorps l(1)G0354, anticorps l(1)G0359, anticorps myc, anticorps MYC proto-oncogene, bHLH transcription factor, anticorps v-myc myelocytomatosis viral oncogene homolog, anticorps nucleolar protein 3 (apoptosis repressor with CARD domain), anticorps myelocytomatosis oncogene, anticorps MYC proto-oncogene, bHLH transcription factor a, anticorps MYC proto-oncogene, bHLH transcription factor L homeolog, anticorps MYC proto-oncogene, bHLH transcription factor S homeolog, anticorps v-myc myelocytomatosis viral oncogene homolog (avian), anticorps MYC proto-oncogene, bHLH transcription factor b, anticorps CG10798 gene product from transcript CG10798-RB, anticorps MYC, anticorps LOC100136746, anticorps Nol3, anticorps Myc, anticorps myca, anticorps myc.L, anticorps myc.S, anticorps mycb
    Sujet
    It recognizes a transcription factor of 64-67  kDa, identified as c-myc. Its epitope spans between aa 410-419 (EQKLISEEDL) which is a specific portion of an alpha helical region of human c-myc protein. This mAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or overexpressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease.
    Pathways
    Signalisation p53, Cycle Cellulaire, Sensory Perception of Sound, Transition Metal Ion Homeostasis, Mitotic G1-G1/S Phases, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Positive Regulation of Response to DNA Damage Stimulus, L'effet Warburg
Support technique